Correspondence
Atorvastatin-induced dermatomyositis

https://doi.org/10.1016/S0002-9343(01)00711-2Get rights and content

References (10)

  • J. Hanson et al.

    Lupus-like syndrome associated with simvastatin

    Lancet

    (1998)
  • B. Bannwarth et al.

    Lupuslike syndrome associated with simvastatin

    Arch Intern Med

    (1992)
  • R. Khosla et al.

    Simvastatin-induced lupus erythematosus

    South Med J

    (1998)
  • A. Ahmad et al.

    Simvastatin-induced lupus-like syndrome

    Tenn Med

    (2000)
  • B.B. Schalke et al.

    Pravastatin-associated inflammatory myopathy

    N Engl J Med

    (1992)
There are more references available in the full text version of this article.

Cited by (54)

  • Statins and autoimmunity: State-of-the-art

    2020, Pharmacology and Therapeutics
  • Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)

    2016, Canadian Journal of Cardiology
    Citation Excerpt :

    Statin myotoxicity was first conceived as a direct toxic myopathy that resolves upon discontinuation of the statin. Although predominantly true, this concept was challenged by early reports of inflammatory myopathies associated with statin therapy (ie, PM227 and DM228) but with persistence or worsening of proximal weakness and increases in CK levels despite drug withdrawal. The European Neuromuscular Consortium Muscle Study Group amended the classification of idiopathic inflammatory myopathies (ie, PM, DM, and inclusion body myositis) by adding nonspecific inflammatory myopathy, defined by the presence of inflammatory infiltrate without discrete features of either PM or DM, and defined a new category termed IMNM—characterized by myofibre necrosis with absent or minimal inflammation.229

  • Biochemistry of Statins

    2016, Advances in Clinical Chemistry
    Citation Excerpt :

    Immune factors may, in fact, play a role in the development of statin myopathy/myositis in a certain subset of patients. Indeed, several reports have emerged demonstrating the induction of inflammatory myopathies (i.e., polymyositis and dermatomyositis) by statins in a timeframe consistent with a toxic effect [143–149]. In contrast to these studies, which exhibited robust inflammatory infiltrates on muscle biopsy, an immune myopathy may develop manifesting major histocompatibility-1 upregulation without inflammation [150].

  • Statin induced necrotizing autoimmune myopathy

    2015, Journal of the Neurological Sciences
    Citation Excerpt :

    In the literature, 14 cases of statin associated DM were reported [36]. Among them, only 2 of whom resolved spontaneous after statin discontinuation without immunosuppressive treatment, suggesting a causal relationship [37,38]. The widespread use of statins makes it difficult to exclude a chance association between statins and PM in the remaining cases.

  • Statin myotoxicity: A review of genetic susceptibility factors

    2014, Neuromuscular Disorders
    Citation Excerpt :

    In addition, it is known that statins also have various effects on the immune system [51–57]. These are likely to be relevant to the pathogenesis of some forms of statin-associated myopathy, such as the necrotizing autoimmune myopathy (NAM) [58,59], which is associated with autoantibodies to HMGCoA [56,60], and to the induction of other types of inflammatory myopathies [59,61–71] and autoimmune disorders such as myasthenia gravis [72,73]. The idea of using genetic polymorphisms to predict therapeutic efficacy and toxicity in an individual is attractive, and the use of genetic variants to predict adverse drug reactions has been increasing over the past decade.

View all citing articles on Scopus
View full text